Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY2 | P41231 | 20/20 | 0.84 |
| ▸ | P2RY4 | P51582 | 5/20 | 0.60 |
| ▸ | P2RY6 | Q15077 | 3/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6799800 | 0.92 | P2RY2 (1.00) | P2RY2P2RY4P2RY6 | |
| SCHEMBL6798665 | 0.86 | P2RY2 (0.84) | P2RY2P2RY4P2RY6 | |
| SCHEMBL6794096 | 0.85 | P2RY2 (0.85) | P2RY2P2RY4P2RY6 | |
| SCHEMBL6796407 | 0.84 | P2RY2 (0.83) | P2RY2P2RY4P2RY6 | |
| SCHEMBL6804051 | 0.84 | P2RY2 (0.82) | P2RY2P2RY4P2RY6 | |
| Phosphoric Acid SCHEMBL6799804 | 0.83 | P2RY2 (0.64) | P2RY2P2RY4 | |
| SCHEMBL6799423 | 0.82 | P2RY2 (0.82) | P2RY2P2RY4P2RY6 | |
| SCHEMBL6798825 | 0.81 | P2RY2 (0.82) | P2RY2P2RY4P2RY6 | |
| SCHEMBL6798368 | 0.81 | P2RY2 (0.82) | P2RY2P2RY4P2RY6 | |
| SCHEMBL6794147 | 0.81 | P2RY2 (1.00) | P2RY2P2RY4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040122223-A1 | Non-natural nucleotides and dinucleotides | CELLTECH R & D LIMITED (GB) | 2004-06-24 | — | — | US | claimed |
| EP-1368366-A1 | NON-NATURAL NUCLEOTIDES AND DINUCLEOTIDES | Celltech R & D Limited (GB) | 2003-12-10 | — | — | EP | claimed |
| WO-2002062816-A1 | NON-NATURAL NUCLEOTIDES AND DINUCLEOTIDES | CELLTECH R & D LIMITED (GB) | 2002-08-15 | — | — | WO | claimed |
| US-20040122223-A1 | Non-natural nucleotides and dinucleotides | CELLTECH R & D LIMITED (GB) | 2004-06-24 | — | — | US | disclosed |
| EP-1368366-A1 | NON-NATURAL NUCLEOTIDES AND DINUCLEOTIDES | Celltech R & D Limited (GB) | 2003-12-10 | — | — | EP | disclosed |
| WO-2002062816-A1 | NON-NATURAL NUCLEOTIDES AND DINUCLEOTIDES | CELLTECH R & D LIMITED (GB) | 2002-08-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122223-A1 | Non-natural nucleotides and dinucleotides | P2RY1, P2RY11, P2RY13 | P2RY2 8/4885P2RY4 6/4885P2RY6 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.